Investigational Drug Information for Diquafosol
✉ Email this page to a colleague
What is the drug development status for Diquafosol?
Diquafosol is an investigational drug.
There have been 22 clinical trials for Diquafosol.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2021.
The most common disease conditions in clinical trials are Keratoconjunctivitis Sicca, Dry Eye Syndromes, and Eye Diseases. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., He Eye Hospital, and Santen Pharmaceutical Co., Ltd.
There are seventy-eight US patents protecting this investigational drug and zero international patents.
Summary for Diquafosol
| US Patents | 78 |
| International Patents | 1,614 |
| US Patent Applications | 305 |
| WIPO Patent Applications | 148 |
| Japanese Patent Applications | 111 |
| Clinical Trial Progress | Phase 3 (2021-01-01) |
| Vendors | 20 |
Recent Clinical Trials for Diquafosol
| Title | Sponsor | Phase |
|---|---|---|
| Temperature on Evaporative Dry Eye | He Eye Hospital | N/A |
| Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye | He Eye Hospital | N/A |
| Management of DE With IPL in Combination With DQS | He Eye Hospital | N/A |
Clinical Trial Summary for Diquafosol
Top disease conditions for Diquafosol
Top clinical trial sponsors for Diquafosol
US Patents for Diquafosol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Diquafosol | ⤷ Sign Up | Compositions and methods for treatment of short telomere disorders | Prescient Pharma, LLC (Canton, MA) | ⤷ Sign Up |
| Diquafosol | ⤷ Sign Up | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | Parion Sciences, Inc. (Durham, NC) | ⤷ Sign Up |
| Diquafosol | ⤷ Sign Up | 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors | Chiesi Farmaceutici S.p.A. (Parma, IT) | ⤷ Sign Up |
| Diquafosol | ⤷ Sign Up | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Sign Up |
| Diquafosol | ⤷ Sign Up | Aminoester derivatives | CHIESI FARMACEUTICI S.p.A. (Parma, IT) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Diquafosol
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Diquafosol | Argentina | AR101175 | 2034-07-10 | ⤷ Sign Up |
| Diquafosol | Taiwan | TW201609726 | 2034-07-10 | ⤷ Sign Up |
| Diquafosol | Taiwan | TWI687419 | 2034-07-10 | ⤷ Sign Up |
| Diquafosol | World Intellectual Property Organization (WIPO) | WO2016007731 | 2034-07-10 | ⤷ Sign Up |
| Diquafosol | Australia | AU2013363218 | 2032-12-17 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
